CLAIM CARD
The human evidence base for Curcumin inflammaging spans multiple clinical populations, outcome domains, and study designs, yielding a heterogeneous and sometimes contradictory body of findings. Lamichhane 2025, in a pilot trial of curcumin in prediabetic older adults, similarly found null effects on most immune and metabolic markers, with only select glucose homeostasis parameters reaching significance (P = 0.044). The contradiction between positive RCTs in diabetes-associated inflammation (Yaikwawong 2025, Yaikwawong 2025b) and null or negative trials in other inflammatory contexts (Mansour 2025, Saleh 2025) suggests that Curcumin inflammaging effects may be disease-context-dependent rather than uniformly anti-inflammatory across human populations.
Evidence grade: exploratory
Contradiction status: none
Publication: 2ed54f5a-fbc9-45ec-8fa9-5be79af12b17
Provenance: Derivation Web chain
Citation Support
source_1Flensted-Jensen 2025source_2Flensted-Jensen 2025bsource_3Xu 2025source_4El-Rakabawy 2025source_5Schonenberger 2025